Pharmacology Department, College of Medicine, Minia University, Egypt; Pharmacology Department, College of Pharmacy, Jouf University, Saudi Arabia.
Pharmacol Res. 2020 Jul;157:104874. doi: 10.1016/j.phrs.2020.104874. Epub 2020 Apr 30.
Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Further, BCG vaccination is being considered for clinical trials aiming to test its potential for lowering COVID-19 morbidity and mortality. This article illustrates some structural and functional relationships that may gather these drugs and the author, basing on a combined pathophysiological and pharmacological approach, recommends the FDA-approved antidiarrhea drug; nitazoxanide, which has been previously suggested but unfortunately widely ignored, to be tested in combination with azithromycin for their potential activity against SARS CoV-2, soonest. The author also recommends testing their combined administration as early during the clinical course of COVID-19 as possible. Further, basing on the same represented concept, the author suggests more trials for interferons to be tested against SARS CoV-2, especially in severe and critical COVID-19 cases.
阿奇霉素已被证明对严重急性呼吸综合征冠状病毒 2 具有临床疗效；伊维菌素也表现出显著的实验疗效，有可能用于 2019 年冠状病毒病。此外，卡介苗接种正在考虑进行临床试验，旨在测试其降低 COVID-19 发病率和死亡率的潜力。本文阐述了一些结构和功能关系，这些药物和作者可能会聚集在一起，作者基于综合病理生理学和药理学方法，建议测试已获 FDA 批准的抗腹泻药物硝唑尼特，与阿奇霉素联合使用，以测试其对 SARS-CoV-2 的潜在活性，越快越好。作者还建议尽快在 COVID-19 的临床病程中尽早测试它们的联合给药。此外，基于相同的代表性概念，作者建议针对 SARS-CoV-2 测试更多的干扰素试验，特别是在严重和危急的 COVID-19 病例中。
